A multicenter phase 1/2 clinical trial designed to assess the safety and efficacy of intratumoral injection of the TLR9 agonist SD-101 in combination with low-dose radiation therapy in treatment-naive patients with indolent lymphoma showed that almost all patients had tumor shrinkage at the treatment site without treatment-related grade 4 or serious adverse events (82). The gene discussed is TLR9; the disease is neoplasm.